Last reviewed · How we verify
Placebo (matched to ivacaftor)
Placebo (matched to ivacaftor) is a Small molecule drug developed by Vertex Pharmaceuticals Incorporated. It is currently in Phase 3 development for Matched to ivacaftor in clinical trials.
This drug has no therapeutic effect.
This drug has no therapeutic effect. Used for Matched to ivacaftor in clinical trials.
At a glance
| Generic name | Placebo (matched to ivacaftor) |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems and serves as a control in clinical trials.
Approved indications
- Matched to ivacaftor in clinical trials
Common side effects
Key clinical trials
- Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion (PHASE2)
- The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor (PHASE2)
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) (PHASE3)
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation (PHASE3)
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation (PHASE3)
- Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 (PHASE2)
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (PHASE2)
- A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (matched to ivacaftor) CI brief — competitive landscape report
- Placebo (matched to ivacaftor) updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI